2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: Executive summary

Journal of Thoracic and Cardiovascular Surgery

Volumn 142, Issue 6, 2011, Pages 1303-1338

  Gersh, Bernard J ^a   Maron, Barry J ^a   Bonow, Robert O ^a   Dearani, Joseph A ^a   Fifer, Michael A ^a   Link, Mark S ^a   Naidu, Srihari S ^a   Nishimura, Rick A ^a   Ommen, Steve R ^a   Rakowski, Harry ^a   Seidman, Christine E ^a   Towbin, Jeffrey A ^a   Udelson, James E ^a   Yancy, Clyde W ^a   Jacobs, Alice K ^a   Smith Jr , Sidney C ^a   Anderson, Jeffrey L ^a   Albert, Nancy M ^a   Buller, Christopher E ^a   Creager, Mark A ^a   Ettinger, Steven M ^a   Guyton, Robert A ^a   Halperin, Jonathan L ^a   Hochman, Judith S ^a   Krumholz, Harlan M ^a   Kushner, Frederick G ^a   Ohman, E Magnus ^a   Page, Richard L ^a   Stevenson, William G ^a   Tarkington, Lynn G ^a   more..

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; ALPHA TROPOMYOSIN; AMIODARONE; ANTICOAGULANT AGENT; ANTIVITAMIN K; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGITALIS; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISOPYRAMIDE; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; FLECAINIDE; INOTROPIC AGENT; MYOSIN BINDING PROTEIN C; MYOSIN HEAVY CHAIN BETA; NIFEDIPINE; NORADRENALIN; PHENYLEPHRINE; PROPAFENONE; TROPONIN I; TROPONIN T; VERAPAMIL;

ALCOHOL SEPTAL ABLATION; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ARTIFICIAL HEART PACEMAKER; BLOOD PRESSURE FLUCTUATION; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR RISK; CARDIOVASCULAR SURGERY; CLINICAL FEATURE; CLINICAL PRACTICE; CORONARY ARTERY DISEASE; DEFIBRILLATOR; DEPRESSION; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DRUG DOSE TITRATION; DRUG MEGADOSE; DYSPNEA; ECHOCARDIOGRAPHY; FAMILY HISTORY; FATIGUE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SCREENING; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE ANEURYSM; HEART LEFT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE SEPTUM DEFECT; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; HYPOTENSION; LIGHT CHAIN; LOW DRUG DOSE; MEDICAL HISTORY; MITRAL VALVE DISEASE; OCCUPATIONAL HAZARD; PATHOPHYSIOLOGY; PATIENT SELECTION; PHYSICAL ACTIVITY; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RECREATION; REVIEW; STRESS ECHOCARDIOGRAPHY; SUDDEN DEATH; SURVIVAL RATE; SYNCOPE; TRANSAORTIC SEPTAL MYECTOMY; TREATMENT OUTCOME;

EID: 81255163417     PISSN: 00225223     EISSN: 1097685X     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2011.10.019     Document Type: Article

References (371)

1. ACCF/AHA Task Force on Practice Guidelines. Methodologies and Policies from the ACCF/AHA Task Force on Practice Guidelines. Available at: http://assets.cardiosource.com/Methodology-Manual-for-ACC-AHA-Writing- Committees.pdf and http://circ.ahajournals.org/site/manual/index.xhtml. Accessed July 11, 2011.
2. B.J. Gersh, B.J. Maron, and R.O. Bonow 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Thorac Cardiovasc Surg 142 2011 e153-203
3. D. Teare Asymmetrical hypertrophy of the heart in young adults Br Heart J 20 1958 1 8
4. E. Braunwald, C.T. Lambert, and S.D. Rockoff Idiopathic Hypertrophic subaortic stenosis, I: a description of the disease based upon an analysis of 64 patients Circulation 30 suppl 4 1964 119
5. M. Arad, B.J. Maron, and J.M. Gorham Glycogen storage diseases presenting as hypertrophic cardiomyopathy N Engl J Med 352 2005 362 372
6. C.Y. Ho, N.K. Sweitzer, and B. McDonough Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy Circulation 105 2002 2992 2997 (Pubitemid 34693832)
7. H. Morita, H.L. Rehm, and A. Menesses Shared genetic causes of cardiac hypertrophy in children and adults N Engl J Med 358 2008 1899 1908 (Pubitemid 351620110)
8. H. Niimura, L.L. Bachinski, and S. Sangwatanaroj Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy N Engl J Med 338 1998 1248 1257 (Pubitemid 28216578)
9. S.L. Van Driest, M.J. Ackerman, and S.R. Ommen Prevalence and severity of "benign" mutations in the beta-myosin heavy chain, cardiac troponin T, and alpha-tropomyosin genes in hypertrophic cardiomyopathy Circulation 106 2002 3085 3090 (Pubitemid 35440293)
10. S.L. Van Driest, M.A. Jaeger, and S.R. Ommen Comprehensive analysis of the beta-myosin heavy chain gene in 389 unrelated patients with hypertrophic cardiomyopathy J Am Coll Cardiol 44 2004 602 610 (Pubitemid 39078187)
11. I. Christiaans, I.M. van Langen, and E. Birnie Genetic counseling and cardiac care in predictively tested hypertrophic cardiomyopathy mutation carriers: the patients perspective Am J Med Genet A 149A 2009 1444 1451
12. S. Michie, D. French, and A. Allanson Information recall in genetic counselling: a pilot study of its assessment Patient Educ Couns 32 1997 93 100 (Pubitemid 27395983)
13. S. Michie, A. Allanson, and D. Armstrong Objectives of genetic counselling: differing views of purchasers, providers and users J Public Health Med 20 1998 404 408 (Pubitemid 29019825)
14. K. Offit, E. Groeger, and S. Turner The "duty to warn" a patients family members about hereditary disease risks JAMA 292 2004 1469 1473 (Pubitemid 39258340)
15. I. Christiaans, I.M. van Langen, and E. Birnie Quality of life and psychological distress in hypertrophic cardiomyopathy mutation carriers: a cross-sectional cohort study Am J Med Genet A 149A 2009 602 612
16. S. Fokstuen, R. Lyle, and A. Munoz A DNA resequencing array for pathogenic mutation detection in hypertrophic cardiomyopathy Hum Mutat 29 2008 879 885 (Pubitemid 351794139)
17. I. Olivotto, F. Girolami, and M.J. Ackerman Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy Mayo Clin Proc 83 2008 630 638 (Pubitemid 351810562)
18. B.J. Maron, H. Niimura, and S.A. Casey Development of left ventricular hypertrophy in adults in hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C gene mutations J Am Coll Cardiol 38 2001 315 321 (Pubitemid 32721755)
19. A. Rosenzweig, H. Watkins, and D.S. Hwang Preclinical diagnosis of familial hypertrophic cardiomyopathy by genetic analysis of blood lymphocytes N Engl J Med 325 1991 1753 1760
20. M. Spada, S. Pagliardini, and M. Yasuda High incidence of later-onset Fabry disease revealed by newborn screening Am J Hum Genet 79 2006 31 40 (Pubitemid 43927374)
21. J.C. Moolman, V.A. Corfield, and B. Posen Sudden death due to troponin T mutations J Am Coll Cardiol 29 1997 549 555 (Pubitemid 27116096)
22. A. Woo, H. Rakowski, and J.C. Liew Mutations of the beta myosin heavy chain gene in hypertrophic cardiomyopathy: critical functional sites determine prognosis Heart 89 2003 1179 1185 (Pubitemid 37168122)
23. C.Y. Ho, H.M. Lever, and R. DeSanctis Homozygous mutation in cardiac troponin T: implications for hypertrophic cardiomyopathy Circulation 102 2000 1950 1955
24. J. Ingles, A. Doolan, and C. Chiu Compound and double mutations in patients with hypertrophic cardiomyopathy: implications for genetic testing and counseling J Med Genet 42 2005 e59
25. S.L. Van Driest, V.C. Vasile, and S.R. Ommen Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy J Am Coll Cardiol 44 2004 1903 1910 (Pubitemid 39424094)
26. B. Jeschke, K. Uhl, and B. Weist A high risk phenotype of hypertrophic cardiomyopathy associated with a compound genotype of two mutated beta-myosin heavy chain genes Hum Genet 102 1998 299 304 (Pubitemid 28185218)
27. I. Christiaans, R.H. Lekanne dit Deprez, and I.M. van Langen Ventricular fibrillation in MYH7-related hypertrophic cardiomyopathy before onset of ventricular hypertrophy Heart Rhythm 6 2009 1366 1369
28. P.S. Andersen, O. Havndrup, and L. Hougs Diagnostic yield, interpretation, and clinical utility of mutation screening of sarcomere encoding genes in Danish hypertrophic cardiomyopathy patients and relatives Hum Mutat 30 2009 363 370
29. I. Christiaans, E. Birnie, and I.M. van Langen The yield of risk stratification for sudden cardiac death in hypertrophic cardiomyopathy myosin-binding protein C gene mutation carriers: focus on predictive screening Eur Heart J 31 2010 842 848
30. M. Michels, O.I. Soliman, and J. Phefferkorn Disease penetrance and risk stratification for sudden cardiac death in asymptomatic hypertrophic cardiomyopathy mutation carriers Eur Heart J 30 2009 2593 2598
31. P.M. Elliott, J.R. Gimeno, and M.T. Tome Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy Eur Heart J 27 2006 1933 1941 (Pubitemid 44297366)
32. B.J. Maron, D.D. Savage, and J.K. Wolfson Prognostic significance of 24 hour ambulatory electrocardiographic monitoring in patients with hypertrophic cardiomyopathy: a prospective study Am J Cardiol 48 1981 252 257 (Pubitemid 11019058)
33. B.J. Maron, W.J. McKenna, and G.K. Danielson American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy J Am Coll Cardiol 42 2003 1687 1713
34. L. Monserrat, P.M. Elliott, and J.R. Gimeno Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients J Am Coll Cardiol 42 2003 873 879 (Pubitemid 37059747)
35. A.S. Adabag, M.A. Kuskowski, and B.J. Maron Determinants for clinical diagnosis of hypertrophic cardiomyopathy Am J Cardiol 98 2006 1507 1511 (Pubitemid 44781428)
36. L.C. Afonso, J. Bernal, and J.J. Bax Echocardiography in hypertrophic cardiomyopathy: the role of conventional and emerging technologies JACC Cardiovasc Imaging 1 2008 787 800
37. M.A. Fifer, and G.J. Vlahakes Management of symptoms in hypertrophic cardiomyopathy Circulation 117 2008 429 439
38. H.G. Klues, A. Schiffers, and B.J. Maron Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients J Am Coll Cardiol 26 1995 1699 1708
39. B.J. Maron Hypertrophic cardiomyopathy: a systematic review JAMA 287 2002 1308 1320 (Pubitemid 34250486)
40. G.S. Soor, A. Luk, and E. Ahn Hypertrophic cardiomyopathy: current understanding and treatment objectives J Clin Pathol 62 2009 226 235
41. E.D. Wigle, Z. Sasson, and M.A. Henderson Hypertrophic cardiomyopathy: the importance of the site and the extent of hypertrophy: a review Prog Cardiovasc Dis 28 1985 1 83 (Pubitemid 15237515)
42. E.D. Wigle, H. Rakowski, and B.P. Kimball Hypertrophic cardiomyopathy: clinical spectrum and treatment Circulation 92 1995 1680 1692
43. J. Binder, S.R. Ommen, and B.J. Gersh Echocardiography-guided genetic testing in hypertrophic cardiomyopathy: septal morphological features predict the presence of myofilament mutations Mayo Clin Proc 81 2006 459 467
44. J.M. Bos, J.A. Towbin, and M.J. Ackerman Diagnostic, prognostic, and therapeutic implications of genetic testing for hypertrophic cardiomyopathy J Am Coll Cardiol 54 2009 201 211
45. R.E. Hershberger, J. Cowan, and A. Morales Progress with genetic cardiomyopathies: screening, counseling, and testing in dilated, hypertrophic, and arrhythmogenic right ventricular dysplasia/cardiomyopathy Circ Heart Fail 2 2009 253 261
46. B.J. Maron, J.G. Seidman, and C.E. Seidman Proposal for contemporary screening strategies in families with hypertrophic cardiomyopathy J Am Coll Cardiol 44 2004 2125 2132 (Pubitemid 39576030)
47. M.L. Schwartz, G.F. Cox, and A.E. Lin Clinical approach to genetic cardiomyopathy in children Circulation 94 1996 2021 2038 (Pubitemid 26349318)
48. P.P. Dimitrow, and J.S. Dubiel Echocardiographic risk factors predisposing to sudden cardiac death in hypertrophic cardiomyopathy Heart 91 2005 93 94 (Pubitemid 39665005)
49. G.K. Efthimiadis, D.G. Parcharidou, and G. Giannakoulas Left ventricular outflow tract obstruction as a risk factor for sudden cardiac death in hypertrophic cardiomyopathy Am J Cardiol 104 2009 695 699
50. K.M. Harris, P. Spirito, and M.S. Maron Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy Circulation 114 2006 216 225 (Pubitemid 44297115)
51. B.J. Maron, I. Olivotto, and P. Spirito Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population Circulation 102 2000 858 864
52. M.S. Maron, I. Olivotto, and S. Betocchi Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy N Engl J Med 348 2003 295 303 (Pubitemid 36119984)
53. S.R. Ommen, P.M. Shah, and A.J. Tajik Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy: past, present and future Heart 94 2008 1276 1281
54. P. Sorajja, R.A. Nishimura, and B.J. Gersh Outcome of mildly symptomatic or asymptomatic obstructive hypertrophic cardiomyopathy: a long-term follow-up study J Am Coll Cardiol 54 2009 234 241
55. L.E. Grigg, E.D. Wigle, and W.G. Williams Transesophageal Doppler echocardiography in obstructive hypertrophic cardiomyopathy: clarification of pathophysiology and importance in intraoperative decision making J Am Coll Cardiol 20 1992 42 52
56. T.H. Marwick, W.J. Stewart, and H.M. Lever Benefits of intraoperative echocardiography in the surgical management of hypertrophic cardiomyopathy J Am Coll Cardiol 20 1992 1066 1072
57. E.H. Yu, A.S. Omran, and E.D. Wigle Mitral regurgitation in hypertrophic obstructive cardiomyopathy: relationship to obstruction and relief with myectomy J Am Coll Cardiol 36 2000 2219 2225
58. L. Faber, H. Seggewiss, and D. Welge Echo-guided percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: 7 years of experience Eur J Echocardiogr 5 2004 347 355 (Pubitemid 39194099)
59. D. Monakier, A. Woo, and T. Puri Usefulness of myocardial contrast echocardiographic quantification of risk area for predicting postprocedural complications in patients undergoing septal ethanol ablation for obstructive hypertrophic cardiomyopathy Am J Cardiol 94 2004 1515 1522 (Pubitemid 40268453)
60. S.F. Nagueh, N.M. Lakkis, and Z.X. He Role of myocardial contrast echocardiography during nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy J Am Coll Cardiol 32 1998 225 229 (Pubitemid 28351066)
61. P. Sorajja, U. Valeti, and R.A. Nishimura Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy Circulation 118 2008 131 139
62. S. Carasso, A. Woo, and H. Yang Myocardial mechanics explains the time course of benefit for septal ethanol ablation for hypertrophic cardiomyopathy J Am Soc Echocardiogr 21 2008 493 499
63. V.L. Fernandes, C. Nielsen, and S.F. Nagueh Follow-up of alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: the Baylor and Medical University of South Carolina experience 1996 to 2007 JACC Cardiovasc Interv 1 2008 561 570
64. D.S. Jassal, T.G. Neilan, and M.A. Fifer Sustained improvement in left ventricular diastolic function after alcohol septal ablation for hypertrophic obstructive cardiomyopathy Eur Heart J 27 2006 1805 1810 (Pubitemid 44297385)
65. S.R. Ommen, B.J. Maron, and I. Olivotto Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy J Am Coll Cardiol 46 2005 470 476 (Pubitemid 41040288)
66. A. Woo, W.G. Williams, and R. Choi Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy Circulation 111 2005 2033 2041 (Pubitemid 40577897)
67. D.M. Yoerger, M.H. Picard, and I.F. Palacios Time course of pressure gradient response after first alcohol septal ablation for obstructive hypertrophic cardiomyopathy Am J Cardiol 97 2006 1511 1514
68. M.S. Maron, I. Olivotto, and A.G. Zenovich Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction Circulation 114 2006 2232 2239 (Pubitemid 44789498)
69. M.V. Sherrid, I. Barac, and W.J. McKenna Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy J Am Coll Cardiol 45 2005 1251 1258 (Pubitemid 40523146)
70. Q. Ciampi, S. Betocchi, and R. Lombardi Hemodynamic determinants of exercise-induced abnormal blood pressure response in hypertrophic cardiomyopathy J Am Coll Cardiol 40 2002 278 284 (Pubitemid 34756288)
71. I. Olivotto, B.J. Maron, and A. Montereggi Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy J Am Coll Cardiol 33 1999 2044 2051
72. N. Sadoul, K. Prasad, and P.M. Elliott Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy Circulation 96 1997 2987 2991 (Pubitemid 27500099)
73. M.P. Frenneaux, P.J. Counihan, and A.L. Caforio Abnormal blood pressure response during exercise in hypertrophic cardiomyopathy Circulation 82 1990 1995 2002
74. J.C. Moon, N.G. Fisher, and W.J. McKenna Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography Heart 90 2004 645 649 (Pubitemid 38668538)
75. C. Rickers, N.M. Wilke, and M. Jerosch-Herold Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy Circulation 112 2005 855 861 (Pubitemid 41170072)
76. M.S. Maron, J.J. Finley, and J.M. Bos Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy Circulation 118 2008 1541 1549
77. M.S. Maron, B.J. Maron, and C. Harrigan Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance J Am Coll Cardiol 54 2009 220 228
78. M.S. Maron, J.R. Lesser, and B.J. Maron Management implications of massive left ventricular hypertrophy in hypertrophic cardiomyopathy significantly underestimated by echocardiography but identified by cardiovascular magnetic resonance Am J Cardiol 105 2010 1842 1843
79. A.S. Adabag, B.J. Maron, and E. Appelbaum Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance J Am Coll Cardiol 51 2008 1369 1374 (Pubitemid 351443083)
80. M.S. Maron, E. Appelbaum, and C.J. Harrigan Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy Circ Heart Fail 1 2008 184 191
81. R. Rubinshtein, J.F. Glockner, and S.R. Ommen Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy Circ Heart Fail 3 2010 51 58
82. R. OHanlon, A. Grasso, and M. Roughton Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy J Am Coll Cardiol 56 2010 867 874
83. J.C. Moon, W.J. McKenna, and J.A. McCrohon Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance J Am Coll Cardiol 41 2003 1561 1567 (Pubitemid 36543376)
84. C.A. Gange, M.S. Link, and M.S. Maron Utility of cardiovascular magnetic resonance in the diagnosis of Anderson-Fabry disease Circulation 120 2009 e96 e97
85. A.M. Maceira, J. Joshi, and S.K. Prasad Cardiovascular magnetic resonance in cardiac amyloidosis Circulation 111 2005 186 193 (Pubitemid 40139730)
86. J.C. Moon, B. Sachdev, and A.G. Elkington Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease: evidence for a disease specific abnormality of the myocardial interstitium Eur Heart J 24 2003 2151 2155 (Pubitemid 37486535)
87. R.F. Redberg, E.J. Benjamin, and V. Bittner ACCF/AHA 2009 performance measures for primary prevention of cardiovascular disease in adults J Am Coll Cardiol 54 2009 1364 1405
88. B.J. Maron, B.R. Chaitman, and M.J. Ackerman Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases Circulation 109 2004 2807 2816 (Pubitemid 38744555)
89. P. Spirito, C.E. Seidman, and W.J. McKenna The management of hypertrophic cardiomyopathy N Engl J Med 336 1997 775 785 (Pubitemid 27113973)
90. A.G. Adelman, P.M. Shah, and R. Gramiak Long-term propranolol therapy in muscular subaortic stenosis Br Heart J 32 1970 804 811
91. L.S. Cohen, and E. Braunwald Amelioration of angina pectoris in idiopathic hypertrophic subaortic stenosis with beta-adrenergic blockade Circulation 35 1967 847 851
92. M.D. Flamm, D.C. Harrison, and E.W. Hancock Muscular subaortic stenosis: prevention of outflow obstruction with propranolol Circulation 38 1968 846 858
93. M.J. Frank, A.M. Abdulla, and M.I. Canedo Long-term medical management of hypertrophic obstructive cardiomyopathy Am J Cardiol 42 1978 993 1001
94. D.C. Harrison, E. Braunwald, and G. Glick Effects of beta adrenergic blockade on the circulation with particular reference to observations in patients with hypertrophic subaortic stenosis Circulation 29 1964 84 98
95. R.E. Stenson, M.D. Flamm Jr., and D.C. Harrison Hypertrophic subaortic stenosis: clinical and hemodynamic effects of long-term propranolol therapy Am J Cardiol 31 1973 763 773
96. R.H. Swanton, I.A. Brooksby, and B.S. Jenkins Hemodynamic studies of beta blockade in hypertrophic obstructive cardiomyopathy Eur J Cardiol 5 1977 327 341 (Pubitemid 8179428)
97. E.D. Wigle, A.G. Adelman, and C.H. Felderhof Medical and surgical treatment of the cardiomyopathies Circ Res 35 suppl II 1974 196 207
98. R.O. Bonow, D.R. Rosing, and S.L. Bacharach Effects of verapamil on left ventricular systolic function and diastolic filling in patients with hypertrophic cardiomyopathy Circulation 64 1981 787 796 (Pubitemid 11030133)
99. S.E. Epstein, and D.R. Rosing Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy Circulation 64 1981 437 441 (Pubitemid 11061609)
100. D.R. Rosing, K.M. Kent, and B.J. Maron Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy, II: effects on exercise capacity and symptomatic status Circulation 60 1979 1208 1213 (Pubitemid 10215863)
101. D.R. Rosing, K.M. Kent, and J.S. Borer Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy, I: hemodynamic effects Circulation 60 1979 1201 1207 (Pubitemid 10215862)
102. D.R. Rosing, J.R. Condit, and B.J. Maron Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy, III: effects of long-term administration Am J Cardiol 48 1981 545 553 (Pubitemid 11014401)
103. E. Braunwald, and P.A. Ebert Hemodynamic alterations in idiopathic hypertrophic subaortic stenosis induced by sympathomimetic drugs Am J Cardiol 10 1962 489 495
104. E.D. Wigle, P.R. David, and C.J. Labroose Muscular subaortic stenosis: the interrelation of wall tension, outflow tract "distending pressure" and orifice radius Am J Cardiol 15 1965 761 772
105. J.H. Haley, L.J. Sinak, and A.J. Tajik Dynamic left ventricular outflow tract obstruction in acute coronary syndromes: an important cause of new systolic murmur and cardiogenic shock Mayo Clin Proc 74 1999 901 906 (Pubitemid 29430359)
106. B.P. Kimball, S. Bui, and E.D. Wigle Acute dose-response effects of intravenous disopyramide in hypertrophic obstructive cardiomyopathy Am Heart J 125 1993 1691 1697 (Pubitemid 23169485)
107. C. Pollick, B. Kimball, and M. Henderson Disopyramide in hypertrophic cardiomyopathy, I: hemodynamic assessment after intravenous administration Am J Cardiol 62 1988 1248 1251
108. C. Pollick Disopyramide in hypertrophic cardiomyopathy, II: noninvasive assessment after oral administration Am J Cardiol 62 1988 1252 1255
109. M. Sherrid, E. Delia, and E. Dwyer Oral disopyramide therapy for obstructive hypertrophic cardiomyopathy Am J Cardiol 62 1988 1085 1088 (Pubitemid 18267570)
110. E. Braunwald, R.D. Bloodwell, and L.I. Goldberg Studies on digitalis, IV: observation in man on the effects of digitalis preparations on the contractility of the non-failing heart and on total vascular resistance J Clin Invest 40 1961 52 59
111. E. Braunwald, E.C. Brockenbrough, and R.L. Frye Studies on digitalis, V: comparison of the effects of ouabain on left ventricular dynamics in valvular aortic stenosis and hypertrophic subaortic stenosis Circulation 26 1962 166 173
112. E.H. Sonnenblick, J.F. Williams Jr, and G. Glick Studies on digitalis, XV: effects of cardiac glycosides on myocardial force-velocity relations in the nonfailing human heart Circulation 34 1966 532 539
113. L. Bergfeldt, K. Schenck-Gustafsson, and R. Dahlqvist Comparative class 1 electrophysiologic and anticholinergic effects of disopyramide and its main metabolite (mono-N-dealkylated disopyramide) in healthy humans Cardiovasc Drugs Ther 6 1992 529 537
114. J.S. Birkhead, and E.M. Vaughan Williams Dual effect of disopyramide on atrial and atrioventricular conduction and refractory periods Br Heart J 39 1977 657 660 (Pubitemid 8180743)
115. G. Jensen, and A. Uhrenholt Circulatory effects of intravenous disopyramide in heart failure J Int Med Res 4 1976 42 45
116. M. Lara, G.D. Oakley, and D. Rowbotham Potentially dangerous effect of disopyramide on atrioventricular conduction in a patient on digitalis Br Med J 281 1980 198 (Pubitemid 10073438)
117. F. Morady, M.M. Scheinman, and J. Desai Disopyramide Ann Intern Med 96 1982 337 343 (Pubitemid 12187517)
118. C.E. Robertson, and H.C. Miller Extreme tachycardia complicating the use of disopyramide in atrial flutter Br Heart J 44 1980 602 603 (Pubitemid 11217148)
119. A. Elesber, R.A. Nishimura, and C.S. Rihal Utility of isoproterenol to provoke outflow tract gradients in patients with hypertrophic cardiomyopathy Am J Cardiol 101 2008 516 520 (Pubitemid 351199445)
120. N. Krasnow, E. Rolett, and W.B.J. Hood Reversible obstruction of the ventricular outflow tract Am J Cardiol 11 1963 1 7
121. G.E. Pierce, A.G. Morrow, and E. Braunwald Idiopathic hypertrophic subaortic stenosis, 3: intraoperative studies of the mechanism of obstruction and its hemodynamic consequences Circulation 30 suppl 4 1964 152
122. R.E. Whalen, A.I. Cohen, and R.G. Sumner Demonstration of the dynamic nature of idiopathic hypertrophic subaortic stenosis Am J Cardiol 11 1963 8 17
123. C. van der Lee, B. Scholzel, and J.M. ten Berg Usefulness of clinical, echocardiographic, and procedural characteristics to predict outcome after percutaneous transluminal septal myocardial ablation Am J Cardiol 101 2008 1315 1320
124. S. Firoozi, P.M. Elliott, and S. Sharma Septal myotomy-myectomy and transcoronary septal alcohol ablation in hypertrophic obstructive cardiomyopathy: a comparison of clinical, haemodynamic and exercise outcomes Eur Heart J 23 2002 1617 1624 (Pubitemid 35221567)
125. A. Ralph-Edwards, A. Woo, and B.W. McCrindle Hypertrophic obstructive cardiomyopathy: comparison of outcomes after myectomy or alcohol ablation adjusted by propensity score J Thorac Cardiovasc Surg 129 2005 351 358 (Pubitemid 40169559)
126. N.G. Smedira, B.W. Lytle, and H.M. Lever Current effectiveness and risks of isolated septal myectomy for hypertrophic obstructive cardiomyopathy Ann Thorac Surg 85 2008 127 133 (Pubitemid 350265812)
127. D.A. Theodoro, G.K. Danielson, and R.H. Feldt Hypertrophic obstructive cardiomyopathy in pediatric patients: results of surgical treatment J Thorac Cardiovasc Surg 112 1996 1589 1597
128. F.H. Gietzen, C.J. Leuner, and L. Obergassel Transcoronary ablation of septal hypertrophy for hypertrophic obstructive cardiomyopathy: feasibility, clinical benefit, and short term results in elderly patients Heart 90 2004 638 644 (Pubitemid 38668537)
129. H. Kuhn, T. Lawrenz, and F. Lieder Survival after transcoronary ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy (TASH): a 10 year experience Clin Res Cardiol 97 2008 234 243 (Pubitemid 351464524)
130. D.H. Kwon, S.R. Kapadia, and E.M. Tuzcu Long-term outcomes in high-risk symptomatic patients with hypertrophic cardiomyopathy undergoing alcohol septal ablation JACC Cardiovasc Interv 1 2008 432 438
131. S.F. Nagueh, S.R. Ommen, and N.M. Lakkis Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy J Am Coll Cardiol 38 2001 1701 1706 (Pubitemid 33065457)
132. J.X. Qin, T. Shiota, and H.M. Lever Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery J Am Coll Cardiol 38 2001 1994 2000 (Pubitemid 33116576)
133. J.P. Erwin III, R.A. Nishimura, and M.A. Lloyd Dual chamber pacing for patients with hypertrophic obstructive cardiomyopathy: a clinical perspective in 2000 Mayo Clin Proc 75 2000 173 180 (Pubitemid 30080708)
134. F. Gadler, C. Linde, and C. Daubert Significant improvement of quality of life following atrioventricular synchronous pacing in patients with hypertrophic obstructive cardiomyopathy. Data from 1 year of follow-up PIC study group Pacing In Cardiomyopathy Eur Heart J 20 1999 1044 1050 (Pubitemid 29306788)
135. A.K. Slade, N. Sadoul, and L. Shapiro DDD pacing in hypertrophic cardiomyopathy: a multicentre clinical experience Heart 75 1996 44 49 (Pubitemid 26059968)
136. S.R. Ommen, R.A. Nishimura, and R.W. Squires Comparison of dual-chamber pacing versus septal myectomy for the treatment of patients with hypertrophic obstructive cardiomyopathy: a comparison of objective hemodynamic and exercise end points J Am Coll Cardiol 34 1999 191 196
137. B.J. Maron, R.A. Nishimura, and W.J. McKenna Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy: a randomized, double-blind, crossover study (M-PATHY) Circulation 99 1999 2927 2933 (Pubitemid 29258982)
138. R.A. Nishimura, J.M. Trusty, and D.L. Hayes Dual-chamber pacing for hypertrophic cardiomyopathy: a randomized, double-blind, crossover trial J Am Coll Cardiol 29 1997 435 441 (Pubitemid 27059978)
139. L. Kappenberger, C. Linde, and C. Daubert Pacing in hypertrophic obstructive cardiomyopathy: a randomized crossover study: PIC Study Group Eur Heart J 18 1997 1249 1256 (Pubitemid 27332144)
140. B.J. Maron, and P. Spirito Implications of left ventricular remodeling in hypertrophic cardiomyopathy Am J Cardiol 81 1998 1339 1344 (Pubitemid 28268673)
141. E. Biagini, P. Spirito, and O. Leone Heart transplantation in hypertrophic cardiomyopathy Am J Cardiol 101 2008 387 392 (Pubitemid 351187753)
142. R. Gajarski, D.C. Naftel, and E. Pahl Outcomes of pediatric patients with hypertrophic cardiomyopathy listed for transplant J Heart Lung Transplant 28 2009 1329 1334
143. J.A. Towbin Cardiomyopathy and heart transplantation in children Curr Opin Cardiol 17 2002 274 279 (Pubitemid 34553633)
144. B.J. Maron Risk stratification and role of implantable defibrillators for prevention of sudden death in patients with hypertrophic cardiomyopathy Circ J 74 2010 2271 2282
145. B.J. Maron Contemporary insights and strategies for risk stratification and prevention of sudden death in hypertrophic cardiomyopathy Circulation 121 2010 445 456
146. F. Cecchi, B.J. Maron, and S.E. Epstein Long-term outcome of patients with hypertrophic cardiomyopathy successfully resuscitated after cardiac arrest J Am Coll Cardiol 13 1989 1283 1288 (Pubitemid 19114200)
147. P.M. Elliott, S. Sharma, and A. Varnava Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy J Am Coll Cardiol 33 1999 1596 1601
148. P.M. Elliott, J. Poloniecki, and S. Dickie Sudden death in hypertrophic cardiomyopathy: identification of high risk patients J Am Coll Cardiol 36 2000 2212 2218
149. L. Fananapazir, A.C. Chang, and S.E. Epstein Prognostic determinants in hypertrophic cardiomyopathy: prospective evaluation of a therapeutic strategy based on clinical, Holter, hemodynamic, and electrophysiological findings Circulation 86 1992 730 740
150. S. Maki, H. Ikeda, and A. Muro Predictors of sudden cardiac death in hypertrophic cardiomyopathy Am J Cardiol 82 1998 774 778
151. B.J. Maron, P. Spirito, and W.K. Shen Implantable cardioverter- defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy JAMA 298 2007 405 412 (Pubitemid 47124061)
152. W. McKenna, J. Deanfield, and A. Faruqui Prognosis in hypertrophic cardiomyopathy: role of age and clinical, electrocardiographic and hemodynamic features Am J Cardiol 47 1981 532 538 (Pubitemid 11137648)
153. P. Spirito, C. Autore, and C. Rapezzi Syncope and risk of sudden death in hypertrophic cardiomyopathy Circulation 119 2009 1703 1710
154. B.J. Maron, W.K. Shen, and M.S. Link Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy N Engl J Med 342 2000 365 373 (Pubitemid 30084534)
155. B.J. Maron, and P. Spirito Implantable defibrillators and prevention of sudden death in hypertrophic cardiomyopathy J Cardiovasc Electrophysiol 19 2008 1118 1126
156. J.M. Bos, B.J. Maron, and M.J. Ackerman Role of family history of sudden death in risk stratification and prevention of sudden death with implantable defibrillators in hypertrophic cardiomyopathy Am J Cardiol 106 2010 1481 1486
157. P.M. Elliott, J.R. Gimeno Blanes, and N.G. Mahon Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy Lancet 357 2001 420 424 (Pubitemid 32156140)
158. P. Sorajja, R.A. Nishimura, and S.R. Ommen Use of echocardiography in patients with hypertrophic cardiomyopathy: clinical implications of massive hypertrophy J Am Soc Echocardiogr 19 2006 788 795 (Pubitemid 43817464)
159. P. Spirito, P. Bellone, and K.M. Harris Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy N Engl J Med 342 2000 1778 1785 (Pubitemid 30390237)
160. G. Boriani, B.J. Maron, and W.K. Shen Prevention of sudden death in hypertrophic cardiomyopathy: but which defibrillator for which patient? Circulation 110 2004 e438 e442
161. R.G. Hauser, B.J. Maron, and J.E. Marine Safety and efficacy of transvenous high-voltage implantable cardioverter-defibrillator leads in high-risk hypertrophic cardiomyopathy patients Heart Rhythm 5 2008 1517 1522
162. T. Kleemann, T. Becker, and K. Doenges Annual rate of transvenous defibrillation lead defects in implantable cardioverter-defibrillators over a period of >10 years Circulation 115 2007 2474 2480 (Pubitemid 46763220)
163. W.H. Maisel, M.O. Sweeney, and W.G. Stevenson Recalls and safety alerts involving pacemakers and implantable cardioverter-defibrillator generators JAMA 286 2001 793 799 (Pubitemid 33015572)
164. B.J. Maron, M.J. Ackerman, and R.A. Nishimura Task Force 4: HCM and other cardiomyopathies, mitral valve prolapse, myocarditis, and Marfan syndrome J Am Coll Cardiol 45 2005 1340 1345 (Pubitemid 40523165)
165. A. Pelliccia, R. Fagard, and H.H. Bjornstad Recommendations for competitive sports participation in athletes with cardiovascular disease: a consensus document from the Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology Eur Heart J 26 2005 1422 1445
166. B.J. Maron, S.E. Epstein, and W.C. Roberts Causes of sudden death in competitive athletes J Am Coll Cardiol 7 1986 204 214 (Pubitemid 16132479)
167. B.J. Maron Sudden death in young athletes N Engl J Med 349 2003 1064 1075 (Pubitemid 37098275)
168. B.J. Maron, K.P. Carney, and H.M. Lever Relationship of race to sudden cardiac death in competitive athletes with hypertrophic cardiomyopathy J Am Coll Cardiol 41 2003 974 980 (Pubitemid 36315540)
169. B.J. Maron, J.J. Doerer, and T.S. Haas Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 19802006 Circulation 119 2009 1085 1092
170. D. Corrado, C. Basso, and G. Rizzoli Does sports activity enhance the risk of sudden death in adolescents and young adults? J Am Coll Cardiol 42 2003 1959 1963 (Pubitemid 37485572)
171. V. Fuster, L.E. Ryden, and D.S. Cannom 2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation Circulation 123 2011 e269 e367
172. B.J. Maron, I. Olivotto, and P. Bellone Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy J Am Coll Cardiol 39 2002 301 307 (Pubitemid 34084637)
173. I. Olivotto, F. Cecchi, and S.A. Casey Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy Circulation 104 2001 2517 2524 (Pubitemid 33107372)
174. S.J. Connolly, M.D. Ezekowitz, and S. Yusuf Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
175. M. Tendera, A. Wycisk, and A. Schneeweiss Effect of sotalol on arrhythmias and exercise tolerance in patients with hypertrophic cardiomyopathy Cardiology 82 1993 335 342 (Pubitemid 23245975)
176. T.J. Bunch, T.M. Munger, and P.A. Friedman Substrate and procedural predictors of outcomes after catheter ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy J Cardiovasc Electrophysiol 19 2008 1009 1014
177. D.J. Callans Ablation of atrial fibrillation in the setting of hypertrophic cardiomyopathy J Cardiovasc Electrophysiol 19 2008 1015 1016
178. P. Di Donna, I. Olivotto, and S.D. Delcre Efficacy of catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: impact of age, atrial remodelling, and disease progression Europace 12 2010 347 355
179. F. Gaita, P. Di Donna, and I. Olivotto Usefulness and safety of transcatheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy Am J Cardiol 99 2007 1575 1581 (Pubitemid 46773025)
180. F. Kilicaslan, A. Verma, and E. Saad Efficacy of catheter ablation of atrial fibrillation in patients with hypertrophic obstructive cardiomyopathy Heart Rhythm 3 2006 275 280 (Pubitemid 43264402)
181. V. Bascou, J. Ferrandis, and V. Bauer Obstructive myocardiopathy and pregnancy J Gynecol Obstet Biol Reprod (Paris) 22 1993 309 311
182. S.M. Fitzgerald-Butt, L. Byrne, and C.A. Gerhardt Parental knowledge and attitudes toward hypertrophic cardiomyopathy genetic testing Pediatr Cardiol 31 2010 195 202
183. B.J. Maron Hypertrophic cardiomyopathy: an important global disease Am J Med 116 2004 63 65 (Pubitemid 38050032)
184. Y. Zou, L. Song, and Z. Wang Prevalence of idiopathic hypertrophic cardiomyopathy in China: a population-based echocardiographic analysis of 8080 adults Am J Med 116 2004 14 18 (Pubitemid 38050021)
185. B.J. Maron, J.M. Gardin, and J.M. Flack Prevalence of hypertrophic cardiomyopathy in a general population of young adults: echocardiographic analysis of 4111 subjects in the CARDIA Study Coronary Artery Risk Development in (Young) Adults Circulation 92 1995 785 789
186. B.J. Maron, and S.E. Epstein Hypertrophic cardiomyopathy: a discussion of nomenclature Am J Cardiol 43 1979 1242 1244
187. B.J. Maron, J.A. Towbin, and G. Thiene Contemporary definitions and classification of the cardiomyopathies: an American Heart Association scientific statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention Circulation 113 2006 1807 1816 (Pubitemid 43958474)
188. B.J. Maron, C.E. Seidman, and M.J. Ackerman How should hypertrophic cardiomyopathy be classified? Whats in a name? Dilemmas in nomenclature characterizing hypertrophic cardiomyopathy and left ventricular hypertrophy Circ Cardiovasc Genet 2 2009 81 85
189. B.J. Maron, L. Yeates, and C. Semsarian Clinical challenges of genotype positive ()-phenotype negative (-) family members in hypertrophic cardiomyopathy Am J Cardiol 107 2011 604 608
190. B.J. Maron, and C. Semsarian Emergence of gene mutation carriers and the expanding disease spectrum of hypertrophic cardiomyopathy Eur Heart J 31 2010 1551 1553
191. B.J. Maron, J.S. Gottdiener, and S.E. Epstein Patterns and significance of distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: a wide angle, two dimensional echocardiographic study of 125 patients Am J Cardiol 48 1981 418 428 (Pubitemid 11014383)
192. B.J. Maron, A. Pelliccia, and P. Spirito Cardiac disease in young trained athletes: insights into methods for distinguishing athletes heart from structural heart disease, with particular emphasis on hypertrophic cardiomyopathy Circulation 91 1995 1596 1601
193. B.J. Maron, and A. Pelliccia The heart of trained athletes: cardiac remodeling and the risks of sports, including sudden death Circulation 114 2006 1633 1644 (Pubitemid 44547434)
194. B.J. Maron Distinguishing hypertrophic cardiomyopathy from athletes heart physiological remodelling: clinical significance, diagnostic strategies and implications for preparticipation screening Br J Sports Med 43 2009 649 656
195. A. Pelliccia, N. Kinoshita, and C. Pisicchio Long-term clinical consequences of intense, uninterrupted endurance training in Olympic athletes J Am Coll Cardiol 55 2010 1619 1625
196. A. Pelliccia, F.M. Di Paolo, and E. De Blasiis Prevalence and clinical significance of aortic root dilation in highly trained competitive athletes Circulation 122 2010 698 706 3
197. G.F. Cox, L.A. Sleeper, and A.M. Lowe Factors associated with establishing a causal diagnosis for children with cardiomyopathy Pediatrics 118 2006 1519 1531 (Pubitemid 46393798)
198. F. Scaglia, J.A. Towbin, and W.J. Craigen Clinical spectrum, morbidity, and mortality in 113 pediatric patients with mitochondrial disease Pediatrics 114 2004 925 931 (Pubitemid 41529754)
199. L. Monserrat, J.R. Gimeno-Blanes, and F. Marin Prevalence of Fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy J Am Coll Cardiol 50 2007 2399 2403 (Pubitemid 50011583)
200. R. Alcalai, J.G. Seidman, and C.E. Seidman Genetic basis of hypertrophic cardiomyopathy: from bench to the clinics J Cardiovasc Electrophysiol 19 2008 104 110
201. B.J. Maron, W.C. Roberts, and M. Arad Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy JAMA 301 2009 1253 1259
202. Z. Yang, C.J. McMahon, and L.R. Smith Danon disease as an underrecognized cause of hypertrophic cardiomyopathy in children Circulation 112 2005 1612 1617 (Pubitemid 41324523)
203. S.D. Colan, S.E. Lipshultz, and A.M. Lowe Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: findings from the Pediatric Cardiomyopathy Registry Circulation 115 2007 773 781 (Pubitemid 46294745)
204. B.D. Gelb, and M. Tartaglia Noonan syndrome and related disorders: dysregulated RAS-mitogen activated protein kinase signal transduction Hum Mol Genet 15 Spec No 2 2006 R220 R226
205. A.L. Montalvo, B. Bembi, and M. Donnarumma Mutation profile of the GAA gene in 40 Italian patients with late onset glycogen storage disease type II Hum Mutat 27 2006 999 1006 (Pubitemid 44454052)
206. B. Pandit, A. Sarkozy, and L.A. Pennacchio Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy Nat Genet 39 2007 1007 1012 (Pubitemid 47185177)
207. H.M. van den Hout, W. Hop, and O.P. van Diggelen The natural course of infantile Pompes disease: 20 original cases compared with 133 cases from the literature Pediatrics 112 2003 332 340 (Pubitemid 36951395)
208. F. Ahmad, J.G. Seidman, and C.E. Seidman The genetic basis for cardiac remodeling Annu Rev Genomics Hum Genet 6 2005 185 216 (Pubitemid 41397081)
209. J.G. Seidman, and C. Seidman The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms Cell 104 2001 557 567 (Pubitemid 32201950)
210. B.J. Maron Hypertrophic cardiomyopathy centers Am J Cardiol 104 2009 1158 1159
211. J. Ingles, J.M. Lind, and P. Phongsavan Psychosocial impact of specialized cardiac genetic clinics for hypertrophic cardiomyopathy Genet Med 10 2008 117 120 (Pubitemid 351271723)
212. C.R. Cannan, G.S. Reeder, and K.R. Bailey Natural history of hypertrophic cardiomyopathy: a population-based study, 1976 through 1990 Circulation 92 1995 2488 2495
213. F. Cecchi, I. Olivotto, and A. Montereggi Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population J Am Coll Cardiol 26 1995 1529 1536
214. B.J. Maron, S.A. Casey, and L.C. Poliac Clinical course of hypertrophic cardiomyopathy in a regional United States cohort JAMA 281 1999 650 655 (Pubitemid 29098067)
215. P. Spirito, F. Chiarella, and L. Carratino Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatient population N Engl J Med 320 1989 749 755 (Pubitemid 19093540)
216. B.J. Maron, C. Semsarian, and W.K. Shen Circadian patterns in the occurrence of malignant ventricular tachyarrhythmias triggering defibrillator interventions in patients with hypertrophic cardiomyopathy Heart Rhythm 6 2009 599 602
217. R. Brock Functional obstruction of the left ventricle; acquired aortic subvalvar stenosis Guys Hosp Rep 106 1957 221 238
218. J.M. Criley, and R.J. Siegel Has "obstruction" hindered our understanding of hypertrophic cardiomyopathy? Circulation 72 1985 1148 1154 (Pubitemid 16126793)
219. J.M. Criley, and R.J. Siegel Obstruction is unimportant in the pathophysiology of hypertrophic cardiomyopathy Postgrad Med J 62 1986 515 529 (Pubitemid 16038693)
220. J.M. Criley Unobstructed thinking (and terminology) is called for in the understanding and management of hypertrophic cardiomyopathy J Am Coll Cardiol 29 1997 741 743 (Pubitemid 27128245)
221. B.J. Maron, M.S. Maron, and E.D. Wigle The 50-year history, controversy, and clinical implications of left ventricular outflow tract obstruction in hypertrophic cardiomyopathy: from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy J Am Coll Cardiol 54 2009 191 200
222. J.A. Panza, R.K. Petrone, and L. Fananapazir Utility of continuous wave Doppler echocardiography in the noninvasive assessment of left ventricular outflow tract pressure gradient in patients with hypertrophic cardiomyopathy J Am Coll Cardiol 19 1992 91 99
223. Z. Sasson, P.G. Yock, and L.K. Hatle Doppler echocardiographic determination of the pressure gradient in hypertrophic cardiomyopathy J Am Coll Cardiol 11 1988 752 756 (Pubitemid 18092183)
224. R.E. Falicov, L. Resnekov, and S. Bharati Mid-ventricular obstruction: a variant of obstructive cardiomyopathy Am J Cardiol 37 1976 432 437
225. B.J. Maron, R.A. Nishimura, and G.K. Danielson Pitfalls in clinical recognition and a novel operative approach for hypertrophic cardiomyopathy with severe outflow obstruction due to anomalous papillary muscle Circulation 98 1998 2505 2508 (Pubitemid 29001186)
226. J.B. Geske, P. Sorajja, and S.R. Ommen Left ventricular outflow tract gradient variability in hypertrophic cardiomyopathy Clin Cardiol 32 2009 397 402
227. H. Watkins, W.J. McKenna, and L. Thierfelder Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy N Engl J Med 332 1995 1058 1064
228. H. Watkins, A. Rosenzweig, and D.S. Hwang Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy N Engl J Med 326 1992 1108 1114
229. H. Watkins, L. Thierfelder, and D.S. Hwang Sporadic hypertrophic cardiomyopathy due to de novo myosin mutations J Clin Invest 90 1992 1666 1671
230. F. Girolami, C.Y. Ho, and C. Semsarian Clinical features and outcome of hypertrophic cardiomyopathy associated with triple sarcomere protein gene mutations J Am Coll Cardiol 55 2010 1444 1453
231. A.J. Saltzman, D. Mancini-DiNardo, and C. Li The cardiac myosin binding protein C Arg502Trp mutation: a common cause of hypertrophic cardiomyopathy Circ Res 106 2010 1549 1552
232. M. Kelly, and C. Semsarian Multiple mutations in genetic cardiovascular disease: a marker of disease severity? Circ Cardiovasc Genet 2 2009 182 190
233. C. Chimenti, M. Pieroni, and E. Morgante Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy Circulation 110 2004 1047 1053 (Pubitemid 39319001)
234. F. Rigon, L. Bianchin, and S. Bernasconi Update on age at menarche in Italy: toward the leveling off of the secular trend J Adolesc Health 46 2010 238 244
235. B.J. Maron, M.V. Sherrid, and T.S. Haas Novel hypertrophic cardiomyopathy phenotype: segmental hypertrophy isolated to the posterobasal left ventricular free wall Am J Cardiol 106 2010 750 752
236. C.J. Harrigan, E. Appelbaum, and B.J. Maron Significance of papillary muscle abnormalities identified by cardiovascular magnetic resonance in hypertrophic cardiomyopathy Am J Cardiol 101 2008 668 673 (Pubitemid 351635561)
237. D.H. Kwon, R.M. Setser, and M. Thamilarasan Abnormal papillary muscle morphology is independently associated with increased left ventricular outflow tract obstruction in hypertrophic cardiomyopathy Heart 94 2008 1295 1301
238. L. Choudhury, H. Mahrholdt, and A. Wagner Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy J Am Coll Cardiol 40 2002 2156 2164 (Pubitemid 36005903)
239. M. Al-Mallah, and R.Y. Kwong Clinical application of cardiac CMR Rev Cardiovasc Med 10 2009 134 141
240. O. Bruder, A. Wagner, and C.J. Jensen Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy J Am Coll Cardiol 56 2010 875 887
241. P. Sorajja, S.R. Ommen, and R.A. Nishimura Adverse prognosis of patients with hypertrophic cardiomyopathy who have epicardial coronary artery disease Circulation 108 2003 2342 2348 (Pubitemid 37413540)
242. S.C. Smith Jr, T.E. Feldman, and J.W. Hirshfeld Jr ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention Circulation 113 2006 e166 e286
243. A.T. Yetman, B.W. McCrindle, and C. MacDonald Myocardial bridging in children with hypertrophic cardiomyopathy: a risk factor for sudden death N Engl J Med 339 1998 1201 1209 (Pubitemid 28482129)
244. S.A. Mohiddin, D. Begley, and J. Shih Myocardial bridging does not predict sudden death in children with hypertrophic cardiomyopathy but is associated with more severe cardiac disease J Am Coll Cardiol 36 2000 2270 2278
245. P. Sorajja, S.R. Ommen, and R.A. Nishimura Myocardial bridging in adult patients with hypertrophic cardiomyopathy J Am Coll Cardiol 42 2003 889 894 (Pubitemid 37059749)
246. P.T. OGara, R.O. Bonow, and B.J. Maron Myocardial perfusion abnormalities in patients with hypertrophic cardiomyopathy: assessment with thallium-201 emission computed tomography Circulation 76 1987 1214 1223 (Pubitemid 18007060)
247. V. Dilsizian, R.O. Bonow, and S.E. Epstein Myocardial ischemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy J Am Coll Cardiol 22 1993 796 804 (Pubitemid 23256942)
248. B.J. Maron, J.K. Wolfson, and S.E. Epstein Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy J Am Coll Cardiol 8 1986 545 557 (Pubitemid 16048006)
249. P. Camici, G. Chiriatti, and R. Lorenzoni Coronary vasodilation is impaired in both hypertrophied and nonhypertrophied myocardium of patients with hypertrophic cardiomyopathy: a study with nitrogen-13 ammonia and positron emission tomography J Am Coll Cardiol 17 1991 879 886
250. R.O. Cannon III, C.L. McIntosh, and W.H. Schenke Effect of surgical reduction of left ventricular outflow obstruction on hemodynamics, coronary flow, and myocardial metabolism in hypertrophic cardiomyopathy Circulation 79 1989 766 775 (Pubitemid 19100535)
251. F. Cecchi, I. Olivotto, and R. Gistri Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy N Engl J Med 349 2003 1027 1035 (Pubitemid 37087617)
252. I. Olivotto, F. Cecchi, and R. Gistri Relevance of coronary microvascular flow impairment to long-term remodeling and systolic dysfunction in hypertrophic cardiomyopathy J Am Coll Cardiol 47 2006 1043 1048
253. B.J. Maron, S.A. Casey, and R.G. Hauser Clinical course of hypertrophic cardiomyopathy with survival to advanced age J Am Coll Cardiol 42 2003 882 888 (Pubitemid 37069223)
254. B.J. Maron, R. Mathenge, and S.A. Casey Clinical profile of hypertrophic cardiomyopathy identified de novo in rural communities J Am Coll Cardiol 33 1999 1590 1595
255. M.V. Sherrid, G. Pearle, and D.Z. Gunsburg Mechanism of benefit of negative inotropes in obstructive hypertrophic cardiomyopathy Circulation 97 1998 41 47 (Pubitemid 28036153)
256. R.F. Alvares, and J.F. Goodwin Non-invasive assessment of diastolic function in hypertrophic cardiomyopathy on and off beta adrenergic blocking drugs Br Heart J 48 1982 204 212 (Pubitemid 12067700)
257. C. Bourmayan, A. Razavi, and C. Fournier Effect of propranolol on left ventricular relaxation in hypertrophic cardiomyopathy: an echographic study Am Heart J 109 1985 1311 1316 (Pubitemid 16119649)
258. D.M. Gilligan, W.L. Chan, and J. Joshi A double-blind, placebo-controlled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy J Am Coll Cardiol 21 1993 1672 1679 (Pubitemid 23170444)
259. R.O. Bonow, T.M. Frederick, and S.L. Bacharach Atrial systole and left ventricular filling in hypertrophic cardiomyopathy: effect of verapamil Am J Cardiol 51 1983 1386 1391 (Pubitemid 13133084)
260. R.O. Bonow, H.G. Ostrow, and D.R. Rosing Effects of verapamil on left ventricular systolic and diastolic function in patients with hypertrophic cardiomyopathy: pressure-volume analysis with a nonimaging scintillation probe Circulation 68 1983 1062 1073 (Pubitemid 14238484)
261. R.O. Bonow, V. Dilsizian, and D.R. Rosing Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: short- and long-term effects Circulation 72 1985 853 864 (Pubitemid 16245197)
262. R.O. Bonow, D.F. Vitale, and B.J. Maron Regional left ventricular asynchrony and impaired global left ventricular filling in hypertrophic cardiomyopathy: effect of verapamil J Am Coll Cardiol 9 1987 1108 1116 (Pubitemid 17065771)
263. D.A. Kass, M.R. Wolff, and C.T. Ting Diastolic compliance of hypertrophied ventricle is not acutely altered by pharmacologic agents influencing active processes Ann Intern Med 119 1993 466 473 (Pubitemid 23310107)
264. S. Betocchi, F. Piscione, and M.A. Losi Effects of diltiazem on left ventricular systolic and diastolic function in hypertrophic cardiomyopathy Am J Cardiol 78 1996 451 457 (Pubitemid 26277027)
265. H. Sugihara, Y. Taniguchi, and K. Ito Effects of diltiazem on myocardial perfusion abnormalities during exercise in patients with hypertrophic cardiomyopathy Ann Nucl Med 12 1998 349 354 (Pubitemid 29078773)
266. C. Pollick Muscular subaortic stenosis: hemodynamic and clinical improvement after disopyramide N Engl J Med 307 1982 997 999 (Pubitemid 12018959)
267. U. Sigwart Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy Lancet 346 1995 211 214
268. S.K. Balaram, L. Tyrie, and M.V. Sherrid Resection-plication-release for hypertrophic cardiomyopathy: clinical and echocardiographic follow-up Ann Thorac Surg 86 2008 1539 1544
269. B.A. Austin, D.H. Kwon, and N.G. Smedira Abnormally thickened papillary muscle resulting in dynamic left ventricular outflow tract obstruction: an unusual presentation of hypertrophic cardiomyopathy J Am Soc Echocardiogr 22 2009 105 106
270. H.G. Klues, M.A. Proschan, and A.L. Dollar Echocardiographic assessment of mitral valve size in obstructive hypertrophic cardiomyopathy: anatomic validation from mitral valve specimen Circulation 88 1993 548 555 (Pubitemid 23228054)
271. K. Minakata, J.A. Dearani, and R.A. Nishimura Extended septal myectomy for hypertrophic obstructive cardiomyopathy with anomalous mitral papillary muscles or chordae J Thorac Cardiovasc Surg 127 2004 481 489 (Pubitemid 38180530)
272. F.A. Schoendube, H.G. Klues, and S. Reith Surgical correction of hypertrophic obstructive cardiomyopathy with combined myectomy, mobilisation and partial excision of the papillary muscles Eur J Cardiothorac Surg 8 1994 603 608
273. H.G. Klues, B.J. Maron, and A.L. Dollar Diversity of structural mitral valve alterations in hypertrophic cardiomyopathy Circulation 85 1992 1651 1660
274. R.B. McCully, R.A. Nishimura, and A.J. Tajik Extent of clinical improvement after surgical treatment of hypertrophic obstructive cardiomyopathy Circulation 94 1996 467 471 (Pubitemid 26266133)
275. F. Gadler, C. Linde, and A. Juhlin-Dannfelt Long-term effects of dual chamber pacing in patients with hypertrophic cardiomyopathy without outflow tract obstruction at rest Eur Heart J 18 1997 636 642 (Pubitemid 27182358)
276. U.S. Valeti, R.A. Nishimura, and D.R. Holmes Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy J Am Coll Cardiol 49 2007 350 357 (Pubitemid 46097376)
277. B.J. Maron, S.R. Ommen, and R.A. Nishimura Myths about surgical myectomy: rumors of its death have been greatly exaggerated Am J Cardiol 101 2008 887 889
278. L. Faber, H. Seggewiss, and F.H. Gietzen Catheter-based septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: follow-up results of the TASH-registry of the German Cardiac Society Z Kardiol 94 2005 516 523 (Pubitemid 41124491)
279. V.L. Fernandes, S.F. Nagueh, and W. Wang A prospective follow-up of alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: the Baylor experience (19962002) Clin Cardiol 28 2005 124 130 (Pubitemid 40364503)
280. N.M. Lakkis, S.F. Nagueh, and J.K. Dunn Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: one-year follow-up J Am Coll Cardiol 36 2000 852 855
281. S.M. Chang, S.F. Nagueh, and W.H. Spencer III Complete heart block: determinants and clinical impact in patients with hypertrophic obstructive cardiomyopathy undergoing nonsurgical septal reduction therapy J Am Coll Cardiol 42 2003 296 300 (Pubitemid 36851421)
282. J.X. Qin, T. Shiota, and H.M. Lever Conduction system abnormalities in patients with obstructive hypertrophic cardiomyopathy following septal reduction interventions Am J Cardiol 93 2004 171 175 (Pubitemid 38058725)
283. D.R. Talreja, R.A. Nishimura, and W.D. Edwards Alcohol septal ablation versus surgical septal myectomy: comparison of effects on atrioventricular conduction tissue J Am Coll Cardiol 44 2004 2329 2332 (Pubitemid 39647606)
284. L.H. Cohn, H. Trehan, and J.J. Collins Jr Long-term follow-up of patients undergoing myotomy/myectomy for obstructive hypertrophic cardiomyopathy Am J Cardiol 70 1992 657 660
285. J.W. Kirklin, and F.H. Ellis Jr Surgical relief of diffuse subvalvular aortic stenosis Circulation 24 1961 739 742
286. C.L. McIntosh, and B.J. Maron Current operative treatment of obstructive hypertrophic cardiomyopathy Circulation 78 1988 487 495
287. R. Mohr, H.V. Schaff, and F.J. Puga Results of operation for hypertrophic obstructive cardiomyopathy in children and adults less than 40 years of age Circulation 80 1989 I191 I196
288. A.G. Morrow, and E.C. Brockenbrough Surgical treatment of idiopathic hypertrophic subaortic stenosis: technic and hemodynamic results of subaortic ventriculomyotomy Ann Surg 154 1961 181 189
289. R.C. Robbins, and E.B. Stinson Long-term results of left ventricular myotomy and myectomy for obstructive hypertrophic cardiomyopathy J Thorac Cardiovasc Surg 111 1996 586 594 (Pubitemid 26087722)
290. H.D. Schulte, K. Borisov, and E. Gams Management of symptomatic hypertrophic obstructive cardiomyopathy: long-term results after surgical therapy Thorac Cardiovasc Surg 47 1999 213 218 (Pubitemid 29470003)
291. W.G. Williams, E.D. Wigle, and H. Rakowski Results of surgery for hypertrophic obstructive cardiomyopathy Circulation 76 1987 V104 V108
292. W.G. Williams, and I.M. Rebeyka Surgical intervention and support for cardiomyopathies of childhood Prog Pediatr Cardiol 1 1992 61 71
293. F.A. Schoendube, H.G. Klues, and S. Reith Long-term clinical and echocardiographic follow-up after surgical correction of hypertrophic obstructive cardiomyopathy with extended myectomy and reconstruction of the subvalvular mitral apparatus Circulation 92 suppl 9 1995 II122 II127
294. B.J. Maron Controversies in cardiovascular medicine: surgical myectomy remains the primary treatment option for severely symptomatic patients with obstructive hypertrophic cardiomyopathy Circulation 116 2007 196 206 (Pubitemid 47057526)
295. M.V. Sherrid, F.A. Chaudhry, and D.G. Swistel Obstructive hypertrophic cardiomyopathy: echocardiography, pathophysiology, and the continuing evolution of surgery for obstruction Ann Thorac Surg 75 2003 620 632 (Pubitemid 36184532)
296. B.J. Maron, A.M. Harding, and P. Spirito Systolic anterior motion of the posterior mitral leaflet: a previously unrecognized cause of dynamic subaortic obstruction in patients with hypertrophic cardiomyopathy Circulation 68 1983 282 293 (Pubitemid 13028904)
297. P. Spirito, B.J. Maron, and D.R. Rosing Morphologic determinants of hemodynamic state after ventricular septal myotomy-myectomy in patients with obstructive hypertrophic cardiomyopathy: M mode and two-dimensional echocardiographic assessment Circulation 70 1984 984 995 (Pubitemid 15219358)
298. R.A. Nishimura, and D.R. Holmes Jr Clinical practice: hypertrophic obstructive cardiomyopathy N Engl J Med 350 2004 1320 1327 (Pubitemid 38375367)
299. C.J. McLeod, S.R. Ommen, and M.J. Ackerman Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy Eur Heart J 28 2007 2583 2588 (Pubitemid 350071505)
300. F.J. Ten Cate, O.I. Soliman, and M. Michels Long-term outcome of alcohol septal ablation in patients with obstructive hypertrophic cardiomyopathy: a word of caution Circ Heart Fail 3 2010 362 369
301. B.J. Maron, J.A. Dearani, and S.R. Ommen The case for surgery in obstructive hypertrophic cardiomyopathy J Am Coll Cardiol 44 2004 2044 2053 (Pubitemid 39480744)
302. A.W. ElBardissi, J.A. Dearani, and R.A. Nishimura Septal myectomy after previous septal artery ablation in hypertrophic cardiomyopathy Mayo Clin Proc 82 2007 1516 1522 (Pubitemid 350211700)
303. H.G. Klues, W.C. Roberts, and B.J. Maron Anomalous insertion of papillary muscle directly into anterior mitral leaflet in hypertrophic cardiomyopathy: significance in producing left ventricular outflow obstruction Circulation 84 1991 1188 1197
304. L. Faber, H. Seggewiss, and U. Gleichmann Percutaneous transluminal
305. N.M. Lakkis, S.F. Nagueh, and N.S. Kleiman Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy Circulation 98 1998 1750 1755 (Pubitemid 28492495)
306. L. Faber, H. Seggewiss, and P. Ziemssen Intraprocedural myocardial contrast echocardiography as a routine procedure in percutaneous transluminal septal myocardial ablation: detection of threatening myocardial necrosis distant from the septal target area Catheter Cardiovasc Interv 47 1999 462 466 (Pubitemid 29360372)
307. D.R. Holmes Jr, U.S. Valeti, and R.A. Nishimura Alcohol septal ablation for hypertrophic cardiomyopathy: indications and technique Catheter Cardiovasc Interv 66 2005 375 389 (Pubitemid 41572033)
308. J. Veselka, D. Zemanek, and P. Tomasov Alcohol septal ablation for obstructive hypertrophic cardiomyopathy: ultra-low dose of alcohol (1 ml) is still effective Heart Vessels 24 2009 27 31
309. J. Veselka, R. Duchonova, and J. Palenickova Age-related hemodynamic and morphologic differences in patients undergoing alcohol septal ablation for hypertrophic obstructive cardiomyopathy Circ J 70 2006 880 884 (Pubitemid 43979126)
310. A.L. Baggish, R.N. Smith, and I. Palacios Pathological effects of alcohol septal ablation for hypertrophic obstructive cardiomyopathy Heart 92 2006 1773 1778 (Pubitemid 44851322)
311. R. Flores-Ramirez, N.M. Lakkis, and K.J. Middleton Echocardiographic insights into the mechanisms of relief of left ventricular outflow tract obstruction after nonsurgical septal reduction therapy in patients with hypertrophic obstructive cardiomyopathy J Am Coll Cardiol 37 2001 208 214 (Pubitemid 32051740)
312. H. Kuhn, F.H. Gietzen, and M. Schafers Changes in the left ventricular outflow tract after transcoronary ablation of septal hypertrophy (TASH) for hypertrophic obstructive cardiomyopathy as assessed by transoesophageal echocardiography and by measuring myocardial glucose utilization and perfusion Eur Heart J 20 1999 1808 1817
313. T.H. Park, N.M. Lakkis, and K.J. Middleton Acute effect of nonsurgical septal reduction therapy on regional left ventricular asynchrony in patients with hypertrophic obstructive cardiomyopathy Circulation 106 2002 412 415 (Pubitemid 34803683)
314. N. Lakkis New treatment methods for patients with hypertrophic obstructive cardiomyopathy Curr Opin Cardiol 15 2000 172 177 (Pubitemid 30326639)
315. W. Mazur, S.F. Nagueh, and N.M. Lakkis Regression of left ventricular hypertrophy after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy Circulation 103 2001 1492 1496 (Pubitemid 32226254)
316. W.G. van Dockum, A.M. Beek, and F.J. Ten Cate Early onset and progression of left ventricular remodeling after alcohol septal ablation in hypertrophic obstructive cardiomyopathy Circulation 111 2005 2503 2508 (Pubitemid 40696139)
317. L. Faber, A. Meissner, and P. Ziemssen Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: long term follow up of the first series of 25 patients Heart 83 2000 326 331 (Pubitemid 30313339)
318. F.H. Gietzen, C.J. Leuner, and U. Raute-Kreinsen Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH): catheter interventional treatment for hypertrophic obstructive cardiomyopathy Eur Heart J 20 1999 1342 1354 (Pubitemid 29429721)
319. J.J. Kim, C.W. Lee, and S.W. Park Improvement in exercise capacity and exercise blood pressure response after transcoronary alcohol ablation therapy of septal hypertrophy in hypertrophic cardiomyopathy Am J Cardiol 83 1999 1220 1223 (Pubitemid 29183921)
320. E.R. Serber, S.F. Sears, and C.D. Nielsen Depression, anxiety, and quality of life in patients with obstructive hypertrophic cardiomyopathy three months after alcohol septal ablation Am J Cardiol 100 2007 1592 1597 (Pubitemid 350050865)
321. R.A. Leonardi, E.P. Kransdorf, and D.L. Simel Meta-analyses of septal reduction therapies for obstructive hypertrophic cardiomyopathy: comparative rates of overall mortality and sudden cardiac death after treatment Circ Cardiovasc Interv 3 2010 97 104
322. M. Alam, H. Dokainish, and N.M. Lakkis Hypertrophic obstructive cardiomyopathy-alcohol septal ablation vs. myectomy: a meta-analysis Eur Heart J 30 2009 1080 1087
323. I. Olivotto, S.R. Ommen, and M.S. Maron Surgical myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyopathy: will there ever be a randomized trial? J Am Coll Cardiol 50 2007 831 834 (Pubitemid 47268741)
324. R.A. Nishimura, and S.R. Ommen Septal reduction therapy for obstructive hypertrophic cardiomyopathy and sudden death: what statistics cannot tell you Circ Cardiovasc Interv 3 2010 91 93
325. A.A. Chen, I.F. Palacios, and T. Mela Acute predictors of subacute complete heart block after alcohol septal ablation for obstructive hypertrophic cardiomyopathy Am J Cardiol 97 2006 264 269 (Pubitemid 43139249)
326. L. Faber, D. Welge, and D. Fassbender Percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: managing the risk of procedure-related AV conduction disturbances Int J Cardiol 119 2007 163 167 (Pubitemid 46818511)
327. W. Reinhard, F.J. Ten Cate, and M. Scholten Permanent pacing for complete atrioventricular block after nonsurgical (alcohol) septal reduction in patients with obstructive hypertrophic cardiomyopathy Am J Cardiol 93 2004 1064 1066 (Pubitemid 38479472)
328. W.G. van Dockum, F.J. Ten Cate, and J.M. ten Berg Myocardial infarction after percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: evaluation by contrast-enhanced magnetic resonance imaging J Am Coll Cardiol 43 2004 27 34 (Pubitemid 38045910)
329. C.M. Boltwood Jr, W. Chien, and T. Ports Ventricular tachycardia complicating alcohol septal ablation N Engl J Med 351 2004 1914 1915 (Pubitemid 39426334)
330. Y. Hori, M. Ueda, and T. Nakayama Occurrence of de novo sustained monomorphic ventricular tachycardia induced after percutaneous transluminal alcohol septal myocardial ablation for hypertrophic obstructive cardiomyopathy Int J Cardiol 119 2007 403 407 (Pubitemid 46921260)
331. J. Kazmierczak, Z. Kornacewicz-Jach, and M. Kisly Electrocardiographic changes after alcohol septal ablation in hypertrophic obstructive cardiomyopathy Heart 80 1998 257 262 (Pubitemid 28440344)
332. T. Lawrenz, L. Obergassel, and F. Lieder Transcoronary ablation of septal hypertrophy does not alter ICD intervention rates in high risk patients with hypertrophic obstructive cardiomyopathy Pacing Clin Electrophysiol 28 2005 295 300 (Pubitemid 40604043)
333. J.B. McGregor, A. Rahman, and S. Rosanio Monomorphic ventricular tachycardia: a late complication of percutaneous alcohol septal ablation for hypertrophic cardiomyopathy Am J Med Sci 328 2004 185 188 (Pubitemid 39295868)
334. P.A. Noseworthy, M.A. Rosenberg, and M.A. Fifer Ventricular arrhythmia following alcohol septal ablation for obstructive hypertrophic cardiomyopathy Am J Cardiol 104 2009 128 132
335. R.D. Simon, F.A. Crawford III, and W.H. Spencer III Sustained ventricular tachycardia following alcohol septal ablation for hypertrophic obstructive cardiomyopathy Pacing Clin Electrophysiol 28 2005 1354 1356 (Pubitemid 43951397)
336. F.A. Cuoco, W.H. Spencer III, and V.L. Fernandes Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy J Am Coll Cardiol 52 2008 1718 1723
337. S. Agarwal, E.M. Tuzcu, and M.Y. Desai Updated meta-analysis of septal alcohol ablation versus myectomy for hypertrophic cardiomyopathy J Am Coll Cardiol 55 2010 823 834
338. Deleted in proof.
339. L. Fananapazir, N.D. Epstein, and R.V. Curiel Long-term results of dual-chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy: evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy Circulation 90 1994 2731 2742
340. X. Jeanrenaud, J.J. Goy, and L. Kappenberger Effects of dual-chamber pacing in hypertrophic obstructive cardiomyopathy Lancet 339 1992 1318 1323
341. K. McDonald, E. McWilliams, and B. OKeeffe Functional assessment of patients treated with permanent dual chamber pacing as a primary treatment for hypertrophic cardiomyopathy Eur Heart J 9 1988 893 898
342. C. Linde, F. Gadler, and L. Kappenberger Placebo effect of pacemaker implantation in obstructive hypertrophic cardiomyopathy: PIC Study Group Pacing In Cardiomyopathy Am J Cardiol 83 1999 903 907 (Pubitemid 29143129)
343. R.O. Cannon III, D. Tripodi, and V. Dilsizian Results of permanent dual-chamber pacing in symptomatic nonobstructive hypertrophic cardiomyopathy Am J Cardiol 73 1994 571 576 (Pubitemid 24142590)
344. B.J. Maron, T.S. Haas, and K.M. Shannon Long-term survival after cardiac arrest in hypertrophic cardiomyopathy Heart Rhythm 6 2009 993 997
345. J.R. Gimeno, M. Tome-Esteban, and C. Lofiego Exercise-induced ventricular arrhythmias and risk of sudden cardiac death in patients with hypertrophic cardiomyopathy Eur Heart J 30 2009 2599 2605
346. I. Olivotto, R. Gistri, and P. Petrone Maximum left ventricular thickness and risk of sudden death in patients with hypertrophic cardiomyopathy J Am Coll Cardiol 41 2003 315 321 (Pubitemid 36092203)
347. F. Cecchi, I. Olivotto, and A. Montereggi Prognostic value of non-sustained ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic cardiomyopathy: assessment in an unselected non-referral based patient population Heart 79 1998 331 336 (Pubitemid 28197746)
348. A.M. Kizilbash, S.K. Heinle, and P.A. Grayburn Spontaneous variability of left ventricular outflow tract gradient in hypertrophic obstructive cardiomyopathy Circulation 97 1998 461 466 (Pubitemid 28090218)
349. R. Anan, G. Greve, and L. Thierfelder Prognostic implications of novel beta cardiac myosin heavy chain gene mutations that cause familial hypertrophic cardiomyopathy J Clin Invest 93 1994 280 285 (Pubitemid 24030847)
350. A.J. Marian, and R. Roberts Molecular genetic basis of hypertrophic cardiomyopathy: genetic markers for sudden cardiac death J Cardiovasc Electrophysiol 9 1998 88 99 (Pubitemid 28086489)
351. C. Semsarian, B. Yu, and C. Ryce Sudden cardiac death in familial hypertrophic cardiomyopathy: are "benign" mutations really benign? Pathology 29 1997 305 308
352. M.J. Ackerman, S.L. VanDriest, and S.R. Ommen Prevalence and age-dependence of malignant mutations in the beta-myosin heavy chain and troponin T genes in hypertrophic cardiomyopathy: a comprehensive outpatient perspective J Am Coll Cardiol 39 2002 2042 2048 (Pubitemid 34628288)
353. S.L. Van Driest, B.J. Maron, and M.J. Ackerman From malignant mutations to malignant domains: the continuing search for prognostic significance in the mutant genes causing hypertrophic cardiomyopathy Heart 90 2004 7 8 (Pubitemid 38064529)
354. W.J. McKenna, and E.R. Behr Hypertrophic cardiomyopathy: management, risk stratification, and prevention of sudden death Heart 87 2002 169 176 (Pubitemid 34098386)
355. G. Lin, R.A. Nishimura, and B.J. Gersh Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with hypertrophic cardiomyopathy Heart 95 2009 709 714
356. R.G. Hauser, and B.J. Maron Lessons from the failure and recall of an implantable cardioverter-defibrillator Circulation 112 2005 2040 2042 (Pubitemid 41377424)
357. R.G. Hauser, W.H. Maisel, and P.A. Friedman Longevity of Sprint Fidelis implantable cardioverter-defibrillator leads and risk factors for failure: implications for patient management Circulation 123 2011 358 363
358. A.K. Almquist, J.V. Montgomery, and T.S. Haas Cardioverter-defibrillator implantation in high-risk patients with hypertrophic cardiomyopathy Heart Rhythm 2 2005 814 819 (Pubitemid 41038399)
359. B.J. Maron, J. Shirani, and L.C. Poliac Sudden death in young competitive athletes: clinical, demographic, and pathological profiles JAMA 276 1996 199 204 (Pubitemid 26235063)
360. A. Pelliccia, D.P. Zipes, and B.J. Maron Bethesda Conference 36 and the European Society of Cardiology Consensus Recommendations revisited: a comparison of U.S. and European criteria for eligibility and disqualification of competitive athletes with cardiovascular abnormalities J Am Coll Cardiol 52 2008 1990 1996
361. Y. Doi, and H. Kitaoka Hypertrophic cardiomyopathy in the elderly: significance of atrial fibrillation J Cardiol 37 suppl 1 2001 133 138
362. L. Harris, W.J. McKenna, and E. Rowland Side effects of long-term amiodarone therapy Circulation 67 1983 45 51 (Pubitemid 13222069)
363. W.J. McKenna, L. Harris, and E. Rowland Amiodarone for long-term management of patients with hypertrophic cardiomyopathy Am J Cardiol 54 1984 802 810 (Pubitemid 14006152)
364. W.J. McKenna, L. Harris, and J.P. Mulrow Amiodarone dose titration: a method to minimise side effects during long term therapy Br J Clin Pract Suppl 44 1986 121 131
365. K. Robinson, M.P. Frenneaux, and B. Stockins Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study J Am Coll Cardiol 15 1990 1279 1285 (Pubitemid 20141104)
366. H. Matsubara, S. Nakatani, and S. Nagata Salutary effect of disopyramide on left ventricular diastolic function in hypertrophic obstructive cardiomyopathy J Am Coll Cardiol 26 1995 768 775
367. X. Liu, F. Ouyang, and H. Mavrakis Complete pulmonary vein isolation guided by three-dimensional electroanatomical mapping for the treatment of paroxysmal atrial fibrillation in patients with hypertrophic obstructive cardiomyopathy Europace 7 2005 421 427 (Pubitemid 41130646)
368. M.S. Chen, P.M. McCarthy, and H.M. Lever Effectiveness of atrial fibrillation surgery in patients with hypertrophic cardiomyopathy Am J Cardiol 93 2004 373 375 (Pubitemid 38167444)
369. US Department of Transportation Motor Carrier Safety Administration. Cardiovascular Advisory Panel Guidelines for the Medical Examination of Commercial Motor Vehicle Drivers. Available at: http://www.fmcsa.dot.gov/ documents/cardio.pdf. Accessed May 6, 2011.
370. US Department of Transportation Motor Carrier Safety Administration. Commercial Drivers License Standards; Requirements and Penalties, Section § 383.5. Definitions. Available at: http://www.fmcsa.dot.gov/rules-regulations/ administration/fmcsr/fmcsrruletext.aspx?reg383.5. Accessed May 6, 2011.
371. B.J. Maron, J.A. Barry, and R.S. Poole Pilots, hypertrophic cardiomyopathy, and issues of aviation and public safety Am J Cardiol 93 2004 441 444 (Pubitemid 38221352)